Lynx1 Capital Management »

Proqr Thrapeutics N V shs euro shares owned by Lynx1 Capital Management

Quarter-by-quarter ownership of Proqr Thrapeutics N V shs euro (PRQR) shares owned by Lynx1 Capital Management from 13F filings

Historical chart of Lynx1 Capital Management investment in Proqr Thrapeutics N V shs euro

Tip: Access up to 7 years of quarterly data

All positions including Proqr Thrapeutics N V shs euro held by Lynx1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Proqr Thrapeutics N V shs euro by Lynx1 Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $138k 69k 2.02

More positions owned by Lynx1 Capital Management

Stoke Therapeutics (STOK)
Gh Research Ordinary Shares (GHRS)
Cullinan Oncology (CGEM)
Denali Therapeutics (DNLI)
C4 Therapeutics Com Stk (CCCC)
Xencor (XNCR)
Immatics SHS (IMTX)
Tscan Therapeutics (TCRX)
Passage Bio Com New (PASG)
Korro Bio (KRRO)
Precision Biosciences Com New (DTIL)
Neuphoria Therapeutics (NEUP)
Agios Pharmaceuticals (AGIO)
Cg Oncology (CGON)
Arrowhead Pharmaceuticals (ARWR)

View all positions for Lynx1 Capital Management

Top funds holding Proqr Thrapeutics N V shs euro

Adage Capital Partners GP
Privium Fund Management B.V.
Standard Life Aberdeen
Affinity Asset Advisors
Sio Capital Management
DAFNA Capital Management
Kynam Capital Management
Ikarian Capital
Arrowpoint Asset Management
Platinum Investment Mangement
M28 Capital Management
Point72 Asset Management
UBS Group
Citadel Advisors
Walleye Trading Advisors

View all funds holding Proqr Thrapeutics N V shs euro